Richard J. Daly was appointed Director of Aquestive Therapeutics, Inc., effective October 14, 2026. As of November 6, 2026, Aquestive Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 29, 2026, naming 1 appointment (Form 8-K, September 29, 2026).
Aquestive Therapeutics, Inc. named a new Director on Sep 29. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Aquestive Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Aquestive Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Aquestive Therapeutics, Inc. files it.
Also on the record for Aquestive Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G, by Bass Edward P | 7.5% of the class | 5%+ stakes | Source |
| October 7, 2026 | Stake report, Schedule 13G/A, by BRATTON DOUGLAS K | 0.6% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by RTW Investments, LP | 5.2% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 5.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Aquestive Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aquestive Therapeutics, Inc. and the records around it.
Aquestive Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Aquestive Therapeutics, Inc.
Get an email when Aquestive Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aquestive Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aquestive Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aquestive Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-29 | In | Director | 2026-10-14 | 8-K, 2026-09-29 |
Who leads Aquestive Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Richard J. Daly, appointed, effective 2026-10-14 (filed 2026-09-29).
New leaders reset buying decisions — get the Full Report on Aquestive Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Aquestive Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Aquestive Therapeutics, Inc.Every change, in the filing's words
Appointed: Richard J. Daly, Director, effective 2026-10-14
On September 29, 2026, Aquestive Therapeutics, Inc. (the "Company") announced that the Board of Directors of the Company (the "Board") has elected Richard J. Daly as a director of the Company, effective October 14, 2026.
- Mr. Daly will serve as a Class I director with a term expiring at the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- The Company announced Mr. Daly's election in a press release dated September 29, 2026.
- Mr. Daly was recommended to the Board for election by the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee") after the Nominating Committee considered all candidates, including their backgrounds, relevant experience and professional and personal reputations.
- The Nominating Committee conducted a formal search for director candidates with the assistance of an independent global executive search firm and considered recommendations from members of the Board and management of the Company.
- The Board has affirmatively determined that Mr. Daly has no material relationship with the Company that would affect his independence and that he qualifies as an "independent director" under the applicable listing rules of The Nasdaq Stock Market LLC.
Tools for this story
Each opens in a new tab, filled in for Aquestive Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.